Cooperative effects of INK4a and ras in melanoma susceptibility in vivo

被引:307
作者
Chin, L
Pomerantz, J
Polsky, D
Jacobson, M
Cohen, C
CordonCardo, C
Horner, JW
DePinho, RA
机构
[1] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461
[2] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV DERMATOL,BRONX,NY 10461
[3] MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021
[4] NYU MED CTR,RONALD O PERELMAN DEPT DERMATOL,NEW YORK,NY 10016
关键词
Ink4a; Ink4b; Ras; p53; melanoma; transgenic;
D O I
10.1101/gad.11.21.2822
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The familial melanoma gene (INK4a/MTS1/CDKN2) encodes potent tumor suppressor activity. Although mice null for the ink4a homolog develop a cancer-prone condition, a pathogenetic link to melanoma susceptibility has yet to be established. Here we report that mice with melanocyte-specific expression of activated H-ras(G12V) on an ink4a-deficient background develop spontaneous cutaneous melanomas after a short latency and with high penetrance. Consistent loss of the wild-type ink4a allele was observed in tumors arising in ink4a heterozygous transgenic mice. No homozygous deletion of the neighboring ink4b gene was detected. Moreover, as in human melanomas, the p53 gene remained in a wild-type configuration with no observed mutation or allelic loss. These results show that loss of ink4a and activation of Ras can cooperate to accelerate the development of melanoma and provide the first in vivo experimental evidence for a causal relationship between ink4a deficiency and the pathogenesis of melanoma. In addition, this mouse model affords a system in which to identify and analyze pathways involved in tumor progression against the backdrop of genetic alterations encountered in human melanomas.
引用
收藏
页码:2822 / 2834
页数:13
相关论文
共 80 条
  • [31] HERLYN M, 1993, MOL CELLULAR BIOL ME
  • [32] HIRAMA T, 1995, BLOOD, V86, P841
  • [33] P53 MUTATIONS IN HUMAN CANCERS
    HOLLSTEIN, M
    SIDRANSKY, D
    VOGELSTEIN, B
    HARRIS, CC
    [J]. SCIENCE, 1991, 253 (5015) : 49 - 53
  • [34] Huang TSW, 1996, ANTICANCER RES, V16, P3557
  • [35] GERMLINE P16 MUTATIONS IN FAMILIAL MELANOMA
    HUSSUSSIAN, CJ
    STRUEWING, JP
    GOLDSTEIN, AM
    HIGGINS, PAT
    ALLY, DS
    SHEAHAN, MD
    CLARK, WH
    TUCKER, MA
    DRACOPOLI, NC
    [J]. NATURE GENETICS, 1994, 8 (01) : 15 - 21
  • [36] ABERRANT MELANOGENESIS AND MELANOCYTIC TUMOR-DEVELOPMENT IN TRANSGENIC MICE THAT CARRY A METALLOTHIONEIN RET FUSION GENE
    IWAMOTO, T
    TAKAHASHI, M
    ITO, M
    HAMATANI, K
    OHBAYASHI, M
    WAJJWALKU, W
    ISOBE, K
    NAKASHIMA, I
    [J]. EMBO JOURNAL, 1991, 10 (11) : 3167 - 3175
  • [37] EFFECTS OF AN RB MUTATION IN THE MOUSE
    JACKS, T
    FAZELI, A
    SCHMITT, EM
    BRONSON, RT
    GOODELL, MA
    WEINBERG, RA
    [J]. NATURE, 1992, 359 (6393) : 295 - 300
  • [38] ANALYSIS OF RAS MUTATIONS IN HUMAN MELANOCYTIC LESIONS - ACTIVATION OF THE RAS GENE SEEMS TO BE ASSOCIATED WITH THE NODULAR TYPE OF HUMAN-MALIGNANT MELANOMA
    JAFARI, M
    PAPP, T
    KIRCHNER, S
    DIENER, U
    HENSCHLER, D
    BURG, G
    SCHIFFMANN, D
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (01) : 23 - 30
  • [39] JEN J, 1994, CANCER RES, V54, P6353
  • [40] CELL-CYCLE REGULATORS AND CANCEL
    KAMB, A
    [J]. TRENDS IN GENETICS, 1995, 11 (04) : 136 - 140